Cecilia Mur

Cecilia Mur

Auto-generated profile, based on publicly available information

Cecilia Mur

Eli Lilly and Company, Alcobendas, Spain

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2024 in Cancer Research
Verified
Journal Article
Open access
SBShripad V. Bhagwat
Shripad V. Bhagwat
CMCecilia Mur
Cecilia Mur
MVMatthew Vandekopple
Matthew Vandekopple
BZBaohui Zhao
Baohui Zhao
WSWeihua Shen
Weihua Shen
ADAlfonso de Dios
Alfonso de Dios
Targeting of the estrogen receptor (ER) by antiestrogens is the standard of care for patients with ER+ HER2− advanced/metastatic breast cancer. Although antiestrogens that degrade ERα (fulvestrant) or block estrogen production (aromatase inhibitors) have improved patient outcomes, clinically important challenges remain related to drug administration, limited bioavailability, lack of brain exposure, and acquired resistance due to ESR1 mutations. These limitations indicate a need for more robust ER-targeted therapies. Here, we discovered and characterized imlunestrant, a next-generation potent, brain-penetrant oral selective ER degrader. Imlunestrant degraded ERα and decreased ERα-mediated gene expression both in vitro and in vivo. Cell proliferation and tumor growth in ESR1 wild-type (WT) and mutant models were significantly inhibited by imlunestrant. Combining imlunestrant with abemaciclib (CDK4/6 inhibitor), alpelisib (PI3K inhibitor), or everolimus (mTOR inhibitor) further enhanced tumor growth inhibition, regardless of ESR1 mutational status. In an ER+ breast cancer intracranial tumor model, imlunestrant prolonged survival compared with vehicle or alternative selective ER degrader therapies. Together, these findings support the potential of imlunestrant to degrade ERα and suppress the growth of ESR1-WT and mutant breast cancer, including brain metastatic tumors. Significance: Imlunestrant, a next-generation, brain-penetrant oral ERα degrader, displays potent activity in ESR1 wild-type and mutant breast cancer, enhances combination activity with standard-of-care agents, and inhibits growth of ER+ intracranial tumors.

17 June 2026
Verified
Other
Open access
SBShripad V. Bhagwat
Shripad V. Bhagwat
CMCecilia Mur
Cecilia Mur
MVMatthew Vandekopple
Matthew Vandekopple
BZBaohui Zhao
Baohui Zhao
WSWeihua Shen
Weihua Shen
ADAlfonso de Dios
Alfonso de Dios
In vivo imlunestrant efficacy alone and in combination with abemaciclib, alpelisib, and everolimus in CDX breast cancer models.

17 June 2026
Verified
Other
Open access
SBShripad V. Bhagwat
Shripad V. Bhagwat
CMCecilia Mur
Cecilia Mur
MVMatthew Vandekopple
Matthew Vandekopple
BZBaohui Zhao
Baohui Zhao
WSWeihua Shen
Weihua Shen
ADAlfonso de Dios
Alfonso de Dios
Biochemical and in vitro characterization of imlunestrant.

17 June 2026
Verified
Other
Open access
SBShripad V. Bhagwat
Shripad V. Bhagwat
CMCecilia Mur
Cecilia Mur
MVMatthew Vandekopple
Matthew Vandekopple
BZBaohui Zhao
Baohui Zhao
WSWeihua Shen
Weihua Shen
ADAlfonso de Dios
Alfonso de Dios
In vivo single agent imlunestrant efficacy in ESR1-mutant and wild type xenograft and PDX breast cancer models.

17 February 2025
Verified
Other
Open access
SBShripad V. Bhagwat
Shripad V. Bhagwat
CMCecilia Mur
Cecilia Mur
MVMatthew Vandekopple
Matthew Vandekopple
BZBaohui Zhao
Baohui Zhao
WSWeihua Shen
Weihua Shen
ADAlfonso de Dios
Alfonso de Dios
Statistical survival analysis and body weight change in MCF-7 intracranial model treated with imlunestrant or other SERDs.